DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/sqvsfc/europe) has announced the addition of the "Europe Biosimilars Market & Pipeline Insight" report to their offering.
Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with favorable pricing and reimbursement policies adopted across multiple markets in Europe. The current biosimilars market is highly fragmented in nature due to their accessibility in various therapeutic categories. The European biosimilars market is divided into various categories: Granulocyte-colony stimulating factor (G-CSF or GCSF), erythropoiesis-stimulating agents (ESAs) and somatropin biosimilars, Insulin, mAbs and follitropin. The present market fragmentation is driven by the availability of particular biosimilar products which were introduced over a decade ago. These products created niche among them and resulted in inclination toward a particular segments over a period of time.
One of the most promising factors responsible for the development of biosimilars market is the patent expiration of reference drugs. The European biosimilars market is experiencing tremendous growth as blockbuster biologic drugs are going off-patent. The entry of new biosimilars due to patent expiry into various therapeutic indications has created a new category for the biosimilars. For instance, Ely Lily and Boehringer Ingelheim have already got marketing authorization of their biosimilar insulin in June'2014 even as the current diabetes drug (Lantus) marketed by Sanofi will go off patent in February'2015.
The competitive pricing and reimbursement policies adopted by country specific regulators are also promoting the introduction of biosimilars in European market. The newly introduced biosimilars are approximately 20-30% cheaper and hence results in high level of acceptability among patients and physicians in comparison to originator molecule. The benefits of using the biosimilars include reimbursement provided by many governments which further decreases the financial burden from the patients as result of which they do not revert to originator molecules.
Europe Biosimilars Market & Pipeline Insight Report Highlights:
- Biosimilars Market Overview & Trend Analysis by Country
- Biosimilars Introduction Timeline in Europe
- Biosimilars Development & Market Authorization Guidelines
- Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
- Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
- Europe Biosimilars Pipeline: 93 Biosimilars
- Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine)
Key Topics Covered:
1. Europe Biosimilars Market Overview
2. Europe Biosimilars Market Trend Analysis by Country
3. Biosimilars Introduction Timeline in Europe
4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario
5. Europe Biosimilars Market Dynamics
6. Future Prospectus of Biosimilars in Europe
7. Regulatory & Approval Authorities: EMA & CHMP
8. Biosimilars Development & Market Authorization Guidelines
9. Europe Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
10. Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
11. No Development Reported in Biosimilars Clinical Pipeline
12. Competitive Landscape
- Celltrion Healthcare
- Finox Biotech
- Medice Arzneimittel Pütter
- Stada Arzneimittel
- Teva Pharma
For more information visit http://www.researchandmarkets.com/research/sqvsfc/europe